What is pulsatile vs sustained receptor stimulation?
Pulsatile receptor stimulation alternates between high-agonist and low-agonist phases following each dose; sustained receptor stimulation maintains continuous agonist exposure across the dosing interval. The central design choice distinguishing the short-acting (pulsatile) and long-acting (sustained) GH-axis research compound classes.
What the research literature says
The pulsatile-vs-sustained distinction is most consequential for the GH-axis research-compound class. Native pituitary GH secretion is pulsatile — discrete release pulses several times per day with the largest pulse early in sleep, separated by periods of low plasma GH. Pulsatile GH-axis pharmacology (ipamorelin, CJC-1295 No DAC) mimics this natural rhythm by producing a discrete GH-release pulse following each dose, with plasma GH returning to baseline within hours before the next dose. The Raun ipamorelin work characterised the pulsatile pharmacology (PMID 9849822).
Sustained GH-axis pharmacology (CJC-1295 DAC) produces continuous receptor engagement across multi-day dosing intervals via dramatic half-life extension. The Teichman CJC-1295 DAC clinical-pharmacology work documented prolonged GH and IGF-1 secretion under sustained GHRH-receptor stimulation (PMID 16352683). The Ionescu work examined whether the pituitary’s intrinsic pulse-generation machinery persists during sustained agonist stimulation (PMID 17018654).
For incretin-receptor agonists, the sustained-stimulation framework is the standard — semaglutide and tirzepatide produce continuous receptor engagement at steady state via fatty-acid-sidechain-mediated half-life extension. The pharmacological context differs from GH-axis pharmacology because incretin-receptor desensitisation appears to be less of a clinical concern at the studied dose ranges.
Why this matters in research context
The pulsatile-vs-sustained distinction matters in peptide-research contexts as the framework underlying the choice between short-acting and long-acting compound variants. Researchers studying receptor-engagement-pattern questions specifically should anchor protocol design to the pharmacological-pattern distinction; researchers studying integrated downstream effects across either pattern have more flexibility in compound selection.
Related compounds
- CJC-1295 No DAC 10mg — pulsatile pharmacology
- Ipamorelin 10mg — pulsatile pharmacology
- Tesamorelin 10mg — intermediate-duration pharmacology
Related research questions
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.